Back to Search
Start Over
Treatment patterns in women with postmenopausal osteoporosis using abaloparatide: a real-world observational study.
Treatment patterns in women with postmenopausal osteoporosis using abaloparatide: a real-world observational study.
- Source :
-
Osteoporosis International . Aug2024, Vol. 35 Issue 8, p1407-1415. 9p. - Publication Year :
- 2024
-
Abstract
- Summary: Review of medical records from 173 women with osteoporosis who received abaloparatide treatment revealed that 96.0% had at least one visit for osteoporosis management and 55.5% had medication support group access. The most common reasons for discontinuing treatment were financial (31.2%) and tolerability (22.8%). Most patients (64.8%) completed treatment as prescribed. Purpose: Abaloparatide is approved for the treatment of women with postmenopausal osteoporosis at high risk for fracture. This study evaluated real-world treatment patterns for patients new to abaloparatide, regardless of osteoporosis treatment history. Methods: Data for patients with ≥ 1 prescription for abaloparatide were collected retrospectively from six academic and clinical practice settings across the US. Results: A total of 173 patients were enrolled (mean [SD] age, 69.8 [7.4] years). At the time of abaloparatide treatment initiation, 78.6% had received other osteoporosis medications. Mean (SD) time from discontinuation of osteoporosis medications prior to initiation of abaloparatide was 1.7 (3.2) years. Twenty-four months of follow-up data from the initiation date of abaloparatide was collected from 94.0% of patients and 6.0% of patients had 12–24 months of follow-up. During the follow-up period, 96.0% of patients had at least one visit for osteoporosis management and 55.5% had access to a medication support program. The median duration of therapy was 18.6 months and 105/162 (64.8%) completed abaloparatide treatment as prescribed. The most common reasons for treatment discontinuation were financial (31.2%) and tolerability (22.8%). Following completion of a course of treatment with abaloparatide, 82/162 (50.6%) patients transitioned to another osteoporosis medication. The median time between abaloparatide treatment course completion and the initiation of follow-on medication was 21 days. Conclusion: Most patients completed treatment with abaloparatide as prescribed, and over half continued with an antiresorptive agent. This favorable conduct may be the result of regular follow-up visits and accessibility to both medication and patient support services. [ABSTRACT FROM AUTHOR]
- Subjects :
- *PATIENT compliance
*HEALTH services accessibility
*RESEARCH funding
*ACADEMIC medical centers
*POSTMENOPAUSE
*DESCRIPTIVE statistics
*TREATMENT duration
*RETROSPECTIVE studies
*PARATHYROID hormone
*BONE fractures
*MEDICAL records
*ACQUISITION of data
*RESEARCH
*OSTEOPOROSIS
*DRUGS
*DISEASE risk factors
Subjects
Details
- Language :
- English
- ISSN :
- 0937941X
- Volume :
- 35
- Issue :
- 8
- Database :
- Academic Search Index
- Journal :
- Osteoporosis International
- Publication Type :
- Academic Journal
- Accession number :
- 178655511
- Full Text :
- https://doi.org/10.1007/s00198-024-07070-z